We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Hit With Complete Response Letter on Potential Sarcoma Drug
Merck Hit With Complete Response Letter on Potential Sarcoma Drug
June 8, 2012
The FDA has handed Merck a complete response letter on Taltorvic, a potential maintenance treatment for metastatic soft-tissue and bone sarcomas, calling for additional clinical trials to assess safety and efficacy.